抑制含α5亚基的γ-氨基丁酸A型受体可减轻创伤性脑损伤后的认知缺陷
该研究为实验动物研究,采用闭合性头部自由落体打击法建立成年雄性小鼠创伤性脑损伤模型。伤后1周,在行为学测试前30分钟给予L-655,708(0.5 mg/kg),该药选择性抑制含α5亚基的γ-氨基丁酸A型受体。创伤性脑损伤增加了小鼠在拼箱实验中解决困难任务所需时间,并损害了新物体识别和新位置识别记忆;L-655,708改善了创伤性脑损伤小鼠的问题解决能力和记忆。创伤性脑损伤降低了海马脑片的长时程增强,L-655,708(100 nM灌流)减轻了这一降低。作者认为含α5亚基的γ-氨基丁酸A型受体是创伤性脑损伤所致持续性认知缺陷的新型药物治疗靶点。
要点
- 在成年雄性小鼠闭合性头部自由落体打击模型中,创伤性脑损伤增加了拼箱实验解决困难任务所需时间,并损害了新物体识别和新位置识别记忆。
- 伤后1周、行为学测试前30分钟给予L-655,708(0.5 mg/kg)可改善创伤性脑损伤小鼠的问题解决能力和记忆。
- 创伤性脑损伤降低了海马脑片长时程增强,灌流L-655,708(100 nM)可减轻这一降低。
- 作者认为含α5亚基的γ-氨基丁酸A型受体是创伤性脑损伤所致持续性认知缺陷的新型药物治疗靶点。
适用人群与场景
- 成年雄性小鼠及海马脑片;采用闭合性头部自由落体打击法建立创伤性脑损伤模型,伤后1周进行行为学测试或制备海马脑片。
处置流程与药物剂量
- 伤后1周,在行为学测试前30分钟给予L-655,708(0.5 mg/kg),该药选择性抑制含α5亚基的γ-氨基丁酸A型受体。
- 伤后1周制备海马脑片,在cornu Ammonis 1区灌流L-655,708(100 nM)进行场电位记录研究长时程增强。
研究设计与关键结果
- 实验动物研究:成年雄性小鼠接受闭合性头部自由落体打击致创伤性脑损伤;伤后1周行为学测试前30分钟给予L-655,708(0.5 mg/kg) vs 对照,L-655,708改善了创伤性脑损伤小鼠的问题解决能力和记忆。
- 创伤性脑损伤增加了拼箱实验中解决困难任务所需时间,但未增加简单任务所需时间;创伤性脑损伤损害了新物体识别和新位置识别记忆。
- 创伤性脑损伤降低了海马脑片长时程增强,L-655,708(100 nM)减轻了这一降低。
证据类型、等级与局限
- 证据类型:实验动物研究(成年雄性小鼠及海马脑片)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为含α5亚基的γ-氨基丁酸A型受体是创伤性脑损伤所致持续性认知缺陷的新型药物治疗靶点。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Cognitive deficits after traumatic brain injury are a leading cause of disability worldwide, yet no effective pharmacologic treatments exist to improve cognition. Traumatic brain injury increases proinflammatory cytokines, which trigger excess function of α5 subunit-containing γ-aminobutyric acid type A receptors. In several models of brain injury, drugs that inhibit α5 subunit-containing γ-aminobutyric acid type A receptor function improve cognitive performance. Thus, we postulated that inhibiting α5 subunit-containing γ-aminobutyric acid type A receptors would improve cognitive performance after traumatic brain injury. In addition, because traumatic brain injury reduces long-term potentiation in the hippocampus, a cellular correlate of memory, we studied whether inhibition of α5 subunit-containing γ-aminobutyric acid type A receptors attenuated deficits in long-term potentiation after traumatic brain injury.
DESIGN: Experimental animal study.
SETTING: Research laboratory.
SUBJECTS: Adult male mice and hippocampal brain slices.
INTERVENTIONS: Anesthetized mice were subjected to traumatic brain injury with a closed-head, free-weight drop method. One week later, the mice were treated with L-655,708 (0.5 mg/kg), an inhibitor that is selective for α5 subunit-containing γ-aminobutyric acid type A receptors, 30 minutes before undergoing behavioral testing. Problem-solving abilities were assessed using the puzzle box assay, and memory performance was studied with novel object recognition and object place recognition assays. In addition, hippocampal slices were prepared 1 week after traumatic brain injury, and long-term potentiation was studied using field recordings in the cornu Ammonis 1 region of slices that were perfused with L-655,708 (100 nM).
MEASUREMENTS AND MAIN RESULTS: Traumatic brain injury increased the time required to solve difficult but not simple tasks in the puzzle box assay and impaired memory in the novel object recognition and object place recognition assays. L-655,708 improved both problem solving and memory in the traumatic brain injury mice. Traumatic brain injury reduced long-term potentiation in the hippocampal slices, and L-655,708 attenuated this reduction.
CONCLUSIONS: Pharmacologic inhibition of α5 subunit-containing γ-aminobutyric acid type A receptors attenuated cognitive deficits after traumatic brain injury and enhanced synaptic plasticity in hippocampal slices. Collectively, these results suggest that α5 subunit-containing γ-aminobutyric acid type A receptors are novel targets for pharmacologic treatment of traumatic brain injury-induced persistent cognitive deficits.
参考来源
- Khodaei S, Avramescu S, Wang DS, et al. Inhibiting α5 Subunit-Containing γ-Aminobutyric Acid Type A Receptors Attenuates Cognitive Deficits After Traumatic Brain Injury. Crit Care Med. 2020. PMID: 32205600. doi:10.1097/CCM.0000000000004161
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。